329 related articles for article (PubMed ID: 16774657)
1. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
2. Risperidone long-acting injection in practice - more questions than answers?
Taylor D
Acta Psychiatr Scand; 2006 Jul; 114(1):1-2. PubMed ID: 16774654
[No Abstract] [Full Text] [Related]
3. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
4. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
5. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
7. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of patients on risperidone depot.
Nesvåg R; Tanum L
Nord J Psychiatry; 2005; 59(1):51-5. PubMed ID: 16195099
[TBL] [Abstract][Full Text] [Related]
9. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
10. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
[TBL] [Abstract][Full Text] [Related]
11. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
12. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
Mori T
Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
14. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
15. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of prescription practices of long acting injectable risperidone in French hospitals].
Bret P; Heil M; Queuille E; Bret MC;
Encephale; 2011 May; 37 Suppl 1():S58-65. PubMed ID: 21600335
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
[TBL] [Abstract][Full Text] [Related]
18. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
19. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
20. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.
Belotto KC; Raposo NR; Ferreira AS; Gattaz WF
Clin Ther; 2010 Nov; 32(12):2106-15. PubMed ID: 21118746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
